Preoperative chemotherapy does not adversely affect pancreatic structure and short-term outcome after pancreatectomy

J Gastrointest Surg. 2013 Mar;17(3):488-93. doi: 10.1007/s11605-012-2063-7. Epub 2012 Nov 7.

Abstract

Background: Preoperative chemotherapy (PCHT) has recently been proposed also in patients with resectable pancreatic adenocarcinoma. Few data are currently available on the impact of PCHT on short-term postoperative outcome after pancreatic resection. The objective of this study is to assess the impact of PCHT on pancreatic structure and short-term outcome after surgical resection.

Methods: Fifty consecutive patients successfully underwent resection after PCHT. Each patient was matched with two control patients with pancreatic adenocarcinoma selected from our prospective electronic database. Match criteria were age (±3 years), gender, American Society of Anesthesiologist score, type of resection, pancreatic duct diameter (±1 mm), and tumor size (±5 mm). Primary endpoint was morbidity rate. Secondary endpoints were pancreatic parenchymal structure, mortality rate, and length of hospital stay (LOS).

Results: Both degree of fibrosis and fatty infiltration of the pancreas were similar in the two groups. Overall morbidity rate was 48.0 % in the PCHT group vs. 54.0 % in the control group (p = 0.37). Pancreatic fistula rate was 18.0 % in the PCHT group vs. 25.0 % in the control group (p = 0.41). Mortality was 4.0 % in the PCHT group vs. 2.0 % in the control group (p = 0.60). Mean LOS (days) was 12.7 in the PCHT group vs. 12.4 in the control group (p = 0.74). There was no difference in resection margin status, while the rate of patients without nodal involvement was higher in the PCHT group (46.0 vs. 23.0 %, p = 0.004).

Conclusion: PCHT did not induce significant structural changes in pancreatic parenchyma and did not adversely affect short-term outcome after surgery.

MeSH terms

  • Adenocarcinoma / therapy*
  • Adipose Tissue
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chemotherapy, Adjuvant
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Female
  • Fibrosis
  • Gemcitabine
  • Humans
  • Length of Stay
  • Male
  • Middle Aged
  • Neoadjuvant Therapy
  • Pancreas / drug effects
  • Pancreas / pathology*
  • Pancreatectomy / adverse effects*
  • Pancreatic Fistula / etiology*
  • Pancreatic Neoplasms / therapy*
  • Pancreaticoduodenectomy / adverse effects
  • Postoperative Hemorrhage / etiology*
  • Postoperative Hemorrhage / surgery
  • Time Factors
  • Treatment Outcome

Substances

  • Deoxycytidine
  • Gemcitabine